Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00764972
Other study ID # McG 0713
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received September 30, 2008
Last updated October 17, 2008
Start date October 2007
Est. completion date December 2011

Study information

Verified date October 2008
Source McGill University
Contact Lawrence Panasci
Phone 514-340-8248
Email lpanasci@hotmail.com
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

This is a phase IB/II trial of sorafenib, a new tyrosine kinase inhibition of multiple genes that is active against renal cancer, plus vinorelbine, a chemotherapy agent active in breast cancer.

The investigators are combining these 2 drugs in order to determine if the investigators can increase the activity of vinorelbine in metastatic breast cancer patients.

Patients with measurable metastatic breast cancer without previous chemotherapy for metastatic disease are eligible for the protocol. They will be treated with 2 different dose levels of sorafenib in order to determine the most tolerable dose.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date December 2011
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Female
Age group 19 Years to 65 Years
Eligibility Inclusion Criteria:

- Women affected by histologically proven metastatic breast cancer.

- Tumor not susceptible to therapy with trastuzumab, defined as FISH negative for HER-2 amplification or immunohistochemistry 0-1+ for HER-2 expression.

- Female, age = 18.

- Documented measurable disease by appropriate radiologic imaging according to RECIST criteria (see Appendix E). Lesions in previously irradiated areas are not considered measurable disease, unless progression has been documented post-radiation.

- ECOG performance status 0-1 (see Appendix B)

- Life expectancy > 6 months.

- Adequate bone marrow function, as indicated by:

- Hemoglobin = 90 g/L

- Neutrophils = 1.5 x 109/L

- Platelets = 100 x 109/L

- Adequate renal function, as indicated by serum creatinine =1.5 times the upper limit of normal and/or Creatinine Clearance calculated as >50% lower normal limit, or estimated as = 50 ml/min (Appendix C).

- Adequate liver function, as indicated by:

- bilirubin = 1.5 times upper normal limit;

- AST and ALT = 2 times upper normal limit.

- Left ventricular ejection fraction (LVEF) =50% as measured by either multigated acquisition (MUGA) scan or echocardiogram (ECHO).

- No therapy for breast cancer in the 4 weeks preceding the therapy start.

- Women of childbearing potential must be using adequate contraception and have a negative pregnancy test at the time of enrollment.

- Patient able to understand and give written informed consent.

Exclusion Criteria:

- Patients with locally advanced breast cancer or stage IIIb only.

- Presence of only non-measurable disease.

- Previous (neo)adjuvant chemotherapy with vinorelbine.

- Any previous anti-angiogenic therapy.

- Any previous chemotherapy for metastatic breast cancer. Previous hormonal treatments or radiotherapy for metastatic disease are allowed.

- Radiotherapy, chemotherapy or hormonal therapy for breast cancer in the last 4 weeks prior to starting the study treatment.

- Major surgery within 4 weeks of first study treatment, or minor surgery (including placement of an access device) within 7 days of therapy start.

- Presence of life-threatening disease or central nervous system localizations.

- Evidence of HER-2 positive breast cancer, defined as FISH-positive for amplification or score 3+ by immunohistochemistry.

- Any other possibly active primary tumor, except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.

- Clinically significant hepatic disease with respect to hepatitis B, hepatitis C, cirrhosis or other liver diseases.

- Uncontrolled bacterial, viral or fungal infection.

- Previous history of ischemic disease.

- Patients with previous history of thrombo-embolic events, or with documented risk factors for thrombotic disease other than cancer.

- History of gross hemorrhage within the past 6 months (e.g., hemoptysis or hematuria requiring medical intervention).

- Uncontrolled hypertension.

- Other serious medical conditions, such as uncontrolled cardiac disease, severe pulmonary disease, uncontrolled diabetes.

- Patient exhibiting confusion or disorientation.

- Any condition (medical, social, psychological, geographical) that would prevent adequate follow-up.

- Patient is pregnant, or is breast-feeding, or is unwilling to use adequate contraception.

- Failure to give informed consent.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Sorafenib and Vinorelbine
vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles); sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe.

Locations

Country Name City State
Canada Jewish General Hospital Montreal Quebec

Sponsors (1)

Lead Sponsor Collaborator
McGill University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Confirmed complete response (CR) or partial response (PR), defined according to RECIST criteria, persisting 4 weeks after the initial documentation. unknown No
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2